Work

136PD_PR 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR)

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/s1556-0864(18)30410-6

Authors: J. Mazières, K. Park, C. Lewanski, S. Gadgeel, L. Fehrenbacher, A. Rittmeyer, J-Y. Han, A. Artal-Cortes, F. Braiteh, J. Vansteenkiste

Institutions: Centre Hospitalier Universitaire de Toulouse, Samsung Medical Center, Sungkyunkwan University, Charing Cross Hospital, University of Michigan, Kaiser Permanente Vallejo Medical Center, National Cancer Center, Hospital Universitario Miguel Servet, Comprehensive Cancer Centers of Nevada, KU Leuven

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2797915357

FWCI: 1.774

Cites:

Cited by: 23

Related to: 10